MRCE Administrative Core
MRCE Administrative Core
批准号:
7641628
负责人:
SAMUEL L. STANLEY
金额:
$55.86万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-03-01 至 2009-02-28
关键词:
AccountabilityAdvisory CommitteesAreaBiotechnologyBioterrorismChairpersonChildhoodClassClinicalCommunicable DiseasesConsultCore FacilityEducational workshopEmergency SituationEmerging Communicable DiseasesEnsureEthnic groupEventFacultyFloorFosteringFundingGoalsHousingIndividualInstitutionLettersMedicineMethodologyMicrobiologyMissionMissouriMolecularOccupational activity of managing financesOrganizational ModelsPediatric ResearchPliabilityPostdoctoral FellowProgram DevelopmentProgram Research Project GrantsReagentResearchResearch InstituteResearch PersonnelResearch Project GrantsResearch SupportResearch TrainingResourcesScienceStagingStrategic PlanningTrainingUnited States National Institutes of HealthUniversitiesVirginiaWashingtonWomanWorkauthoritybasebiodefensecareerdayinnovationinterestmedical schoolsmemberprogramsracial and ethnicresponsesymposium
中文摘要
MRCE的组织模式如下图所示。目前,MRCE
包括五个主要的机构合作伙伴,凯斯西储大学,中西部研究
圣路易斯大学医学院、密苏里州大学和华盛顿大学学院
医学。这些机构将容纳核心设施,并主要负责研究和
MRCE的培训任务。在该项目的规划阶段,向所有参与者提供了伙伴地位,
第七区的主要学术中心。其中一些机构选择发展自己的财团
并生成单独的RCE或RCE规划应用程序。然而,为了更好地履行其使命,
在整个第七区的生物防御和新出现的传染病研究和培训中,MRCE将
对来自四个州地区或任何地理上邻近的感兴趣的机构的增加保持开放
没有RCE服务的区域。这些机构将有机会成为正式机构合作伙伴,
MRCEmthis地位将使他们能够容纳核心设施,申请MRCE研究支持,并充分
参与MRCE的治理。来自任何机构或生物技术的个人研究者
在第七区域内,获得NIH或其他政府支持以研究A-C类药物的公司将被
有资格成为MRCE会员。这将使他们有权访问MRCE核心设施,并申请
MRCE研究支持。
MRCE的行政核心将设在传染病司,
华盛顿大学医学院医学系。有关的问责线
财务管理的研究核心设施,研究项目计划,职业生涯规划
方案和应急响应计划通过行政核心进行。管理局
行政核心通过医学系主席(Kenneth Polonsky博士)进行,
和医学院院长(威廉·派克博士,见承诺书)。行政核心
办公室将设在华盛顿大学医学院医学系提供的空间内。
医学在麦克唐纳科学儿科研究大楼的7层。在相邻的楼层,
儿科感染性疾病科和分子微生物学系。的日常
中心的行政管理将由主任进行;在他缺席时,弗吉尼亚米勒博士将担任
代理导演主任将定期与共同主任米勒博士、贝尔什博士和
博士一浦执行委员会和咨询委员会将向主任提供咨询意见。
英文摘要
The organizational model for the MRCE is shown in the figure below. The MRCE currently
encompasses five major institutional partners, Case Western Reserve University, the Midwest Research
Institute, St. Louis University School of Medicine, the University of Missouri, and Washington University School
of Medicine. These institutions will house the Core Facilities and be primarily responsible for the research and
training missions of the MRCE. In the planning stages of the MRCE, partner status was offered to all the
leading academic centers within Region VII. Some of these institutions elected to develop their own consortia
and produce separate RCE or RCE planning applications. However, to best fulfill its mission of fostering
research and training in biodefense and emerging infectious diseases within all of Region VII, the MRCE will
remain open to the addition of interested institutions from the four State area or any geographically proximate
region not served by a RCE. These institutions will have the opportunity to become full institutional partners in
the MRCEmthis status will allow them to house core facilities, to apply for MRCE research support, and to fully
participate in the governance of the MRCE. Individual investigators from any institution or biotechnology
company within Region VII that have NIH or other governmental support to work on class A-C agents will be
eligible for MRCE membership. This will give them the right to access MRCE Core Facilities and apply for
MRCE research support.
The Administrative Core of the MRCE will be located within the Division of Infectious Diseases in the
Department of Medicine at Washington University School of Medicine. The line of accountability regarding the
financial management of the Research Core Facilities, Research Projects Programs, Career Develcpment
Programs, and Emergency Response Plan proceeds through the Administrative Core. Authority for the
Administrative Core proceeds through the Chairman of the Department of Medicine (Dr. Kenneth Polonsky),
and the Dean of the Medical School (Dr. William Peck, see letter of commitment). The Administrative Core
offices will be located in space provided by the Department of Medicine at Washington University School of
Medicine on the 7t"floor of the McDonnell Sciences Pediatric Research Building. On adjacent floors are the
Division of Pediatric Infectious Diseases, and the Department of Molecular Microbiology. The day to day
administration of the Center will be carried by the Director; in his absence, Dr. Virginia Miller will serve as
Acting-Director. The Director will consult on a regular basis with the co-Directors, Dr. Miller, Dr. Belshe, and
Dr. Kazura. The Director will be advised by the Executive Committee and the Advisory Committees.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
An Animal Biosafety Level 3 Laboratory for Stony Brook University
-
批准号:7872073
-
项目类别:
-
资助金额:$1417.96万
-
财政年份:2010
-
负责人:SAMUEL L. STANLEY
-
依托单位:
Overall Career Development
-
批准号:7641691
-
项目类别:
-
资助金额:$66.24万
-
财政年份:2008
-
负责人:SAMUEL L. STANLEY
-
依托单位:
Immunogenetics of Smallpox Vaccination
-
批准号:7641580
-
项目类别:
-
资助金额:$31.99万
-
财政年份:2008
-
负责人:SAMUEL L. STANLEY
-
依托单位:
MRCE for Biodefense and Emerging Infectious Diseases (Development Projects)
-
批准号:7641692
-
项目类别:
-
资助金额:$62.03万
-
财政年份:2008
-
负责人:SAMUEL L. STANLEY
-
依托单位:
MRCE for Biodefense and Emerging Infectious Diseases
-
批准号:6698909
-
项目类别:
-
资助金额:$334.38万
-
财政年份:2003
-
负责人:SAMUEL L. STANLEY
-
依托单位:
MRCE for Biodefense and Emerging Infectious Diseases
-
批准号:6908968
-
项目类别:
-
资助金额:$827.51万
-
财政年份:2003
-
负责人:SAMUEL L. STANLEY
-
依托单位:
MRCE for Biodefense and Emerging Infectious Diseases
-
批准号:7020077
-
项目类别:
-
资助金额:$795.37万
-
财政年份:2003
-
负责人:SAMUEL L. STANLEY
-
依托单位:
MRCE for Biodefense and Emerging Infectious Diseases
-
批准号:7207962
-
项目类别:
-
资助金额:$766.08万
-
财政年份:2003
-
负责人:SAMUEL L. STANLEY
-
依托单位:
MRCE for Biodefense and Emerging Infectious Diseases
-
批准号:6797835
-
项目类别:
-
资助金额:$789.41万
-
财政年份:2003
-
负责人:SAMUEL L. STANLEY
-
依托单位:
MRCE for Biodefense and Emerging Infectious Diseases
-
批准号:7594903
-
项目类别:
-
资助金额:$798.22万
-
财政年份:2003
-
负责人:SAMUEL L. STANLEY
-
依托单位:
Structure-Function of Entamoeba Alcohol Dehydrogenase 2
-
批准号:6733593
-
项目类别:
-
资助金额:$30.6万
-
财政年份:2002
-
负责人:SAMUEL L. STANLEY
-
依托单位:
Structure-Function of Entamoeba Alcohol Dehydrogenase 2
-
批准号:6466309
-
项目类别:
-
资助金额:$30.63万
-
财政年份:2002
-
负责人:SAMUEL L. STANLEY
-
依托单位:
Structure-Function of Entamoeba Alcohol Dehydrogenase 2
-
批准号:6623491
-
项目类别:
-
资助金额:$30.6万
-
财政年份:2002
-
负责人:SAMUEL L. STANLEY
-
依托单位:
Structure-Function of Entamoeba Alcohol Dehydrogenase 2
-
批准号:6890407
-
项目类别:
-
资助金额:$30.6万
-
财政年份:2002
-
负责人:SAMUEL L. STANLEY
-
依托单位:
ENTAMEBA HISTOLYTICA ADH2--A NEW TARGET FOR ANTI-AMEBIC THERAPY
-
批准号:6099926
-
项目类别:
-
资助金额:$10.76万
-
财政年份:1998
-
负责人:SAMUEL L. STANLEY
-
依托单位:
ENTAMEBA HISTOLYTICA ADH2--A NEW TARGET FOR ANTI-AMEBIC THERAPY
-
批准号:6235345
-
项目类别:
-
资助金额:$9.83万
-
财政年份:1997
-
负责人:SAMUEL L. STANLEY
-
依托单位:
PROTECTIVE IMMUNITY TO ENTAMOEBA HISTOLYTICA INFECTION
-
批准号:2671354
-
项目类别:
-
资助金额:$6.47万
-
财政年份:1994
-
负责人:SAMUEL L. STANLEY
-
依托单位:
PROTECTIVE IMMUNITY TO ENTAMOEBA HISTOLYTICA INFECTION
-
批准号:2057405
-
项目类别:
-
资助金额:$6.35万
-
财政年份:1994
-
负责人:SAMUEL L. STANLEY
-
依托单位:
PROTECTIVE IMMUNITY TO ENTAMOEBA HISTOLYTICA INFECTION
-
批准号:2517109
-
项目类别:
-
资助金额:$6.43万
-
财政年份:1994
-
负责人:SAMUEL L. STANLEY
-
依托单位:
PROTECTIVE IMMUNITY TO ENTAMOEBA HISTOLYTICA INFECTION
-
批准号:2057406
-
项目类别:
-
资助金额:$6.39万
-
财政年份:1994
-
负责人:SAMUEL L. STANLEY
-
依托单位:
海外基金